Gland Pharma intimates BSE and NSE about scheduled analyst/institutional investor meetings pursuant to SEBI LODR Regulations.
Company scheduled a one-on-one meeting with Ventura Securities on March 23, 2026, subject to change due to exigencies.
Disclosure signed by Company Secretary Sampath Kumar Pallerlamudi as part of regulatory compliance requirements.